


REMARKS

The above amendments are submitted in order to enter the sequence listing into the Application and to reduce multiple dependencies and to conform the claims more closely to U.S. practice.

Entry of the foregoing amendments and early and favorable processing in the National Phase before the United States Patent and Trademark Office is courteously solicited.

Respectfully submitted,



DAVID A. JACKSON
Attorney for Applicant(s)
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, NJ 07601
(201) 487-5800

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Claims 1-9 have been amended as follows:

1. (Amended) A method [Use of a histacalin protein (as defined herein) in the manufacture of a medicament] for the treatment or prevention of conjunctivitis, said method comprising administering to a patient in need thereof, a medicament comprising therapeutically affective amount of a histacalin protein.

2. (Amended) A method [Use] according to claim 1, wherein said histacalin protein is derived from a blood feeding ectoparasite.

3. (Amended) A method [Use] according to claim 2, wherein said histacalin protein is derived from a tick.

4. (Amended) A method [Use] according to claim 1, wherein said histacalin protein is the MS-HBP1, FS-HBP1, FS-HBP2 or D.RET6 protein, a functional equivalent thereof or an active fragment thereof.

5. (Amended) A method [Use] according to [any one of] claim[s] 1 [to 4] wherein a pharmaceutically-acceptable excipient is also used in the manufacture of the medicament.

6. (Amended) A method [Use] according to claim 5, wherein one or more antihistamine agents or anti-sedative agents is also used in the manufacture of the medicament.

7. (Amended) A pharmaceutical composition comprising a histacalin protein as described in [any one of] claim[s] 1 [to 4], an antihistamine agent and a pharmaceutically-acceptable carrier.

8. (Amended) A method of treating or preventing conjunctivitis comprising administering to a subject a histacalin protein as described in [any one of] claim[s] 1 [to 4], or a pharmaceutical composition as described in [any one of] claim[s] 5 [to 7] in a therapeutically-effective dosage.

9. (Amended) [Use according to any one of claims 1 to 6 or a] A method according to claim 8, wherein said conjunctivitis is non-infective conjunctivitis, preferably allergic conjunctivitis such as seasonal or perennial allergic conjunctivitis.